CONMED Corp stock (US2074101013): focus on growth after latest quarterly results
CONMED Corp, a medical technology company, has released its latest quarterly figures, emphasizing continued growth in minimally invasive surgery and orthopedics. The company's core business revolves around surgical devices and disposables for hospitals, with key revenue drivers in sports medicine and advanced surgical devices. The outlook focuses on profitable growth, despite macroeconomic uncertainties and cost pressures, making it relevant for investors tracking healthcare trends and surgical innovation.
CONMED Corporation Announces Results of 2026 Annual Meeting, Amended By-Laws, and Director Compensation Updates
CONMED Corporation (NYSE: CNMD) has announced significant updates including comprehensive amendments to its bylaws, which took effect on May 19, 2026, to align with Delaware law and market practices. Key changes involve advance notice provisions, director eligibility, and the introduction of proxy access for qualifying shareholders. The company also reported the results of its annual meeting, including the re-election of Patrick J. Beyer, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as its independent auditor for fiscal 2026.
Conmed appoints two directors to board effective July 1
CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026, expanding the board from seven to nine members. Martin, formerly of Johnson & Johnson, will join the audit and strategy committees. Mirviss, with extensive healthcare experience from Boston Scientific, will serve on the compensation and corporate governance committees.
New CONMED (NYSE: CNMD) directors, bylaw changes and 2026 vote outcomes
CONMED Corporation (NYSE: CNMD) made several governance updates, including expanding its board to nine directors and appointing Celine Martin and Jeff Mirviss as independent directors, effective July 1, 2026. The company also amended its bylaws to update advance notice provisions for stockholder nominations and approved the advisory vote on executive compensation and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm for fiscal 2026 at its annual meeting. Additionally, Kimberly Lockwood was appointed interim Corporate Controller and interim Principal Accounting Officer.
Celine Martin and Jeff Mirviss join ConMed board; Kimberly Lockwood named interim controller
ConMed (CNMD) has announced the appointments of Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026. Additionally, Kimberly Lockwood has been named Interim Corporate Controller and Interim Principal Accounting Officer, effective June 1, 2026. These changes are part of the board's decision to increase its size to nine directors.
J&J and Boston Scientific veterans join CONMED's board
CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. Martin, with 30 years at Johnson & Johnson, and Mirviss, with over 35 years at Boston Scientific, bring extensive medical technology experience. Their appointments expand CONMED's board to nine directors and are expected to strengthen the company's governance and long-term strategy for patients, customers, and shareholders.
CONMED Corp stock (US2074101013): shares react to Q1 2026 results and updated full-year outlook
CONMED Corp's shares have been active following the company's Q1 2026 results, which showed revenue and adjusted EPS in line with expectations and a reiterated full-year outlook. The medical device company specializes in surgical products for orthopedics and general surgery, with revenue driven by arthroscopy, electrosurgery, and advanced surgical devices primarily in the US and international markets. Investors are focusing on procedure volume trends, technology adoption, competitive landscape, and the balance between innovation and profitability for future performance.
Number of shareholders of CONMED Corporation – FWB:EC8
This article provides details on the number of shareholders for CONMED Corporation (FWB:EC8) on the Frankfurt Stock Exchange. It indicates market status as closed and presents a table for period, value, change, and change percentage, though the table itself is not populated with data in the provided content. The article is primarily a stub for financial data presentation.
Oppenheimer Asset Management Inc. Has $1.27 Million Stock Holdings in CONMED Corporation $CNMD
Oppenheimer Asset Management Inc. significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 84.1% in Q4, liquidating 165,210 shares to hold 31,195 shares valued at $1.27 million. This move aligns with a cautious analyst sentiment, as JPMorgan and Wells Fargo have lowered their price targets for CONMED, leading to an average "Reduce" rating and a target price of $46.20 from MarketBeat. Despite this, CONMED reported strong Q1 earnings, beating EPS estimates ($0.89 vs. $0.82) and posting revenues of $317.1 million, even with a slight year-over-year decrease.
CONMED (NYSE:CNMD) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded CONMED (NYSE:CNMD) to a "buy" rating from a "strong-buy," reflecting softening analyst sentiment, with MarketBeat showing a consensus "Reduce" rating and a target price of $46.20. Despite this, CONMED exceeded Q1 earnings and revenue estimates, prompting management to raise its 2026 organic growth outlook and announce strategic changes like exiting the GI business and pursuing debt refinancing. Although analysts like Wells Fargo and JPMorgan have cut price targets, indicating modest near-term upside, CONMED's P/E ratio is 20.75 and it maintains a market capitalization of $1.11 billion.
CONMED Corporation (NYSE:CNMD) Q1 2026 Earnings Call Transcript
CONMED Corporation reported its Q1 2026 earnings, with total sales decreasing 1.3% but increasing 3.8% organically after divesting GI product lines. The company affirmed its strategic focus on high-growth, high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, which are key to its long-term strategy. Despite anticipated higher interest expenses from debt refinancing, CONMED maintained its full-year adjusted EPS guidance due to strong Q1 profitability and improved organic growth prospects.
CONMED (NYSE:CNMD) Price Target Lowered to $39.00 at Wells Fargo & Company
Wells Fargo & Company has lowered its price target for CONMED (NYSE:CNMD) shares to $39.00 from $42.00, maintaining an "equal weight" rating. This adjustment follows CONMED's Q1 earnings beat, where it delivered $0.89 EPS against an estimated $0.82 and $317 million in revenue, exceeding the $310.6 million estimate. Despite the strong Q1 performance and raised organic growth outlook, the company faces a near-term revenue headwind due to a strategic exit from certain GI products.
CNMD SEC Filings - Conmed Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Conmed Corp (CNMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It features AI-powered tools to interpret and summarize these documents, highlighting key financial data, operational performance, and strategic actions. The information is crucial for understanding CONMED's financial condition and market activities.
CONMED (NYSE:CNMD) Price Target Lowered to $40.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. has lowered its price target for CONMED (NYSE:CNMD) shares to $40.00 from $43.00, maintaining a "neutral" rating, despite the company beating Q1 earnings and revenue estimates. Several other analysts have also revised their ratings and price targets, resulting in a consensus "Reduce" rating and an average target price of $46.80 for CNMD. The article highlights CONMED's Q1 performance, organic growth outlook, debt refinancing plans, and the near-term sales headwind from exiting certain products.
Earnings call transcript: CONMED beats Q1 2026 forecasts, stock dips
CONMED Corporation (CNMD) reported a Q1 2026 adjusted EPS of $0.89, exceeding the forecasted $0.82, and revenue of $317 million, slightly above expectations. Despite this earnings beat, the stock experienced a 2.26% decline in aftermarket trading due to broader concerns over a revenue decrease and operational challenges, primarily from the exit of its GI product line. The company provided an unchanged full-year EPS guidance of $4.30-$4.45 and raised its organic growth expectation to 5.0%-6.5%, driven by accelerating performance in orthopedics, AirSeal, and smoke evacuation product lines.
CONMED Corp 1Q 2026: Revenue $317M, EPS $0.45— 10-Q Summary
CONMED Corp reported first-quarter 2026 results with revenue slightly down at $317M from $321.3M year-over-year. Despite the revenue dip, net income surged by 129% to $13.8M, and diluted EPS increased by 137% to $0.45, partly due to improved margins and a strategic exit from gastroenterology product lines. Orthopedic sales grew 6.8%, driven by products like BioBrace, while recurring single-use products now account for 85% of revenue, contributing to a 260-basis-point gross margin expansion.
CONMED (NYSE: CNMD) boosts Q1 2026 profit as margins expand
CONMED Corporation (NYSE: CNMD) reported a significant increase in Q1 2026 net income to $13.8 million, up from $6.0 million in Q1 2025, with diluted EPS rising to $0.45 from $0.19, despite a slight dip in net sales to $317.0 million. The improved profitability was primarily driven by an expansion in gross margin to 57.9% due to the termination of a distribution agreement and lower administrative costs. While operating cash flow decreased and the company faces a significant debt maturity in 2027, CONMED is exploring refinancing options and repurchased $37.0 million in stock during the quarter.
CONMED Corporation Announces First Quarter 2026 Financial Results
CONMED Corporation announced its financial results for the first quarter ended March 31, 2026, reporting sales of $317.0 million and diluted net earnings per share of $0.45. The company's adjusted diluted net earnings per share were $0.89. CONMED raised its full-year 2026 organic revenue growth outlook to 5.0% to 6.5% and now expects reported revenue between $1.350 billion and $1.375 billion, while reaffirming its adjusted diluted net earnings per share guidance of $4.30 to $4.45.
Medical device maker CONMED cut sales but raised its 2026 forecast
CONMED Corporation announced its first-quarter 2026 financial results, reporting sales of $317.0 million, a 1.3% decrease year-over-year. Despite the sales slip, largely due to the exit of certain GI products, the company raised its full-year 2026 organic revenue growth outlook to 5.0% to 6.5% on a constant currency basis. CONMED reaffirmed its full-year adjusted diluted net earnings per share guidance of $4.30 to $4.45, reflecting stronger underlying operating performance.
Vanguard reports 1.62M shares in CONMED (NASDAQ: CNMD) as of 03/31/2026
Vanguard Capital Management has filed a Schedule 13G, disclosing a 5.25% beneficial ownership stake in CONMED Corp (NASDAQ: CNMD), totaling 1,619,070 shares as of March 31, 2026. The filing indicates Vanguard's sole dispositive power over all these shares and sole voting power over 235,028 shares. This passive investment is made in the ordinary course of business, with affiliated Vanguard entities exercising control over various managed accounts.
Conmed: Q1 Earnings Snapshot
Conmed Corp. reported strong first-quarter earnings, with net income of $13.8 million, or 45 cents per share. Adjusted earnings of 89 cents per share surpassed Wall Street estimates of 82 cents. The medical technology company also posted revenue of $317 million and provided a positive full-year outlook.
Q1 2026: CONMED (NYSE: CNMD) lifts 2026 sales outlook, EPS $0.45
CONMED (NYSE: CNMD) reported Q1 2026 net sales of $317.0 million, a 1.3% year-over-year decrease, primarily due to the exit of certain gastroenterology products. Despite a decline in adjusted diluted EPS ($0.89 vs. $0.95), GAAP diluted EPS rose to $0.45, and the company raised its full-year 2026 organic constant currency revenue growth outlook to 5.0%–6.5% while reaffirming adjusted diluted EPS guidance of $4.30–$4.45. The updated revenue outlook includes a slight increase in reported revenue expectations, reflecting an estimated favorable foreign exchange impact and adjustments for further gastroenterology portfolio divestiture.
Conmed: Q1 Earnings Snapshot
Conmed Corp. (CNMD) reported strong first-quarter results, with adjusted earnings of 89 cents per share, surpassing Wall Street's expectations of 82 cents per share. The medical technology company achieved total revenue of $317 million for the period. Conmed also provided optimistic full-year guidance, projecting earnings between $4.30 and $4.45 per share and revenue ranging from $1.35 billion to $1.38 billion.
Vanguard Portfolio Management (CNMD) reports 2.12M shares; 6.87% stake
Vanguard Portfolio Management has reported a 6.87% stake in CONMED Corp (CNMD), amounting to 2,120,886 shares of common stock. This disclosure was made in a Schedule 13G filing, indicating Vanguard holds sole dispositive power over all these shares and sole voting power over 44,469 shares. The filing underscores Vanguard's role as a significant passive investor in CONMED, with the reported shares including those held by various Vanguard funds and managed accounts.
CONMED (NYSE:CNMD) Releases Earnings Results, Beats Estimates By $0.07 EPS
CONMED (NYSE:CNMD) announced its quarterly earnings, reporting an adjusted EPS of $0.89, surpassing the consensus estimate by $0.07 despite a 1.3% year-over-year revenue decrease. The company plans to refinance convertible notes in Q2, which is expected to modestly impact adjusted EPS, but remains optimistic about its core growth platforms and raised its 2026 organic revenue guidance. Analysts have a mixed view, with the stock currently holding an average "Reduce" rating.
Here's why you should retain CONMED stock in your portfolio now
This article argues for retaining CONMED stock in an investment portfolio. The content is unavailable, so specific reasons cannot be provided.
CONMED (CNMD) Expected to Announce Quarterly Earnings on Wednesday
CONMED (CNMD) is scheduled to announce its Q1 2026 results after market close on Wednesday, April 29th, with analysts anticipating earnings per share of $0.82 and revenue of $310.59 million. The company's prior quarter performance exceeded estimates, reporting $1.43 EPS against an expected $1.32 and revenue of $373.2 million, an increase of 7.9% year-over-year. Despite a market capitalization near $1.16 billion, the consensus analyst rating for CONMED is "Reduce" with a target price of $50.17, indicating mixed sentiment among analysts.
CONMED Corporation (NYSE:CNMD) Receives Consensus Recommendation of "Reduce" from Analysts
CONMED Corporation (NYSE:CNMD) has received a consensus "Reduce" recommendation from eight analysts, with an average 12-month target price of $50.17. Piper Sandler recently downgraded the stock and cut its price target to $39.00. Shares of CONMED opened at $37.89, trading down 3.9%, and the company recently beat quarterly earnings expectations with an EPS of $1.43 and revenue of $373.2 million.
CONMED Corp stock (US2074101013): Is its surgical device leadership strong enough to unlock new upsi
CONMED Corp (US2074101013) is a key player in surgical devices for minimally invasive procedures, particularly in orthopedics and general surgery, positioning it for steady growth due to aging populations and post-pandemic surgical rebounds. The company's business model focuses on R&D, market expansion, and efficient manufacturing, catering to high-growth segments like sports medicine and bariatric surgery. While facing competition from industry giants, CONMED's niche strategy, innovation in specialized devices, and strong presence in both U.S. and international markets are seen as strong advantages for investors.
CONMED Corp stock (US2074101013): Is its surgical device leadership strong enough to unlock new upsi
CONMED Corp (US2074101013) specializes in surgical devices and implants for minimally invasive procedures, particularly in orthopedics and general surgery, positioning it for steady growth due to aging populations and post-pandemic surgical rebounds. The company's business model relies on a balance of single-use devices and capital equipment, focusing on high-growth segments and R&D for innovative solutions. Analysts generally view CONMED positively due to its niche leadership, growth trajectory, and ability to navigate reimbursement pressures, though risks like supply chain disruptions and regulatory hurdles remain.
How Conmed Corp. - Ordinary Shares (CNMD) Affects Rotational Strategy Timing
This article analyzes Conmed Corp. (CNMD) stock, highlighting a strong near-to-mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 36.7:1 risk-reward short setup and provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging with defined entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Here's why you should retain CONMED stock in your portfolio now
This article argues for retaining CONMED stock in an investment portfolio, likely due to factors suggesting its strong market position or future growth potential. It would delve into the reasons behind this recommendation.
A Look at Conmed Corp (CNMD) After 3.3% Gain -- GF Value $78.09 vs Price $39.73
Conmed Corp (CNMD) shares rose 3.3% to $39.73, positioning the stock significantly below its GF Value™ estimate of $78.09, suggesting it is undervalued by approximately 49.1%. Despite strong fundamentals, including a GF Score™ of 80/100, the company shows notable weaknesses in its valuation and momentum scores. The absence of insider transactions in the last three months indicates a neutral stance from executives regarding the company's near-term performance.
Here's why you should retain CONMED stock in your portfolio now
The article suggests retaining CONMED stock in your portfolio. Without further content, the specific reasons for this recommendation are not detailed.
SG Americas Securities LLC Sells 51,018 Shares of CONMED Corporation $CNMD
SG Americas Securities LLC significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 79.8% in the fourth quarter, selling 51,018 shares. Despite this, other institutions like Tributary Capital, Envestnet, Fisher, and Tudor increased their holdings. Analyst sentiment for CONMED is generally mixed to negative, with an average "Reduce" rating and a target price of $50.17.
Multifilament Suture Market is Booming So Rapidly | Conmed Corporation • Zimmer Biomet • DemeTECH Corporation
A new report by Coherent Market Insights analyzes the Multifilament Suture Market, highlighting its rapid growth driven by rising demand and innovation. The report provides a comprehensive segmentation, competitive analysis of key players like Ethicon, Medtronic, and Conmed, and forecasts substantial growth from 2026 to 2033. It offers insights into market trends, drivers, challenges, and opportunities across various product types and geographical regions, aiming to assist businesses in making informed strategic decisions.
How many employees work at CONMED?
CONMED Corp. currently has 3,790 employees, showing a 1.8% year-over-year growth rate as of December 2025. The company's workforce has seen steady growth in recent years, with a slight decline noted in 2023. Revelio Labs data indicates key metrics such as an average salary of $89.9k and an average tenure of 4.8 years, providing insights into CONMED's workforce dynamics.
Tudor Investment Corp ET AL Boosts Stock Position in CONMED Corporation $CNMD
Tudor Investment Corp ET AL significantly increased its stake in CONMED Corporation (NYSE: CNMD) by 200.9% in the third quarter, acquiring an additional 83,418 shares to hold a total of 124,944 shares valued at $5.88 million. Despite this increase in institutional ownership, brokerages have become more cautious, with a consensus "Reduce" rating and an average price target of $50.17 for the medical technology company. CONMED recently reported stronger-than-expected quarterly earnings, with an EPS of $1.43 against an estimated $1.32, and revenue of $373.2 million, surpassing expectations.
CONMED (CNMD) Price Target Decreased by 12.55% to 55.08
This article reports that the price target for CONMED (CNMD) has been lowered by 12.55% to $55.08. No further details are available as the provided content is incomplete.
[ARS] CONMED Corp SEC Filing
This article reports on an ARS filing by CONMED Corp (CNMD) on April 7, 2026, which is categorized as having a low filing impact and neutral sentiment. The filing is available as a PDF document on SEC EDGAR. The article also provides an overview of CNMD's stock data, recent news, and other SEC filings.
Board moves, CEO pay and buybacks at CONMED (NYSE: CNMD)
CONMED's 2026 proxy statement details upcoming stockholder votes on director elections, executive compensation, and auditor ratification. The company reported $1.375 billion in revenue for 2025, a 5.2% increase, driven by orthopedic and general surgery sales. CONMED also outlined strategic financial decisions including suspending its dividend, authorizing a $150 million share repurchase program, and exiting gastroenterology product lines to focus on core areas.
Allspring Global Investments Holdings LLC Grows Stake in CONMED Corporation $CNMD
Allspring Global Investments Holdings LLC increased its stake in CONMED Corporation by 47.8% in Q4, now holding 416,432 shares valued at approximately $16.87 million. The company recently exceeded Q4 earnings estimates with $1.43 EPS and $373.2 million in revenue, while analysts hold a mixed-to-negative view with a "Reduce" consensus rating and a target price of $50.17. CONMED, a global medical technology company, has a market cap of $1.07 billion.
CNMD Earning Date, Earning Analysis and Earning Prediction
The article provides an earnings analysis and prediction for CNMD, including past quarterly results and future forecasts. It highlights analyst estimates for 2026/Q1, noting unchanged revenue and EPS estimates despite a recent stock price decline, suggesting potential buying opportunities. The analysis also covers historical stock price reactions around earnings announcements and addresses frequently asked questions about CNMD's financial performance and future outlook.
CONMED Corporation Announces Q1 2026 Earnings
CONMED Corporation, a leading medical device provider based in Largo, Florida, announced it will report its first-quarter 2026 financial results on April 29, 2026. This report is highly anticipated by investors and analysts as it provides key insights into the company's performance, the health of the medical device industry, and broader market trends. The company designs, manufactures, and markets a diverse portfolio of surgical instruments and medical devices across orthopedic surgery, general surgery, and patient care solutions.
CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
CONMED Corporation announced that it will release its first-quarter 2026 financial results after market close on Wednesday, April 29, 2026. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results, with access available via pre-registration or webcast on their Investors section. CONMED, a medical technology company, specializes in devices and equipment for various surgical procedures.
CNMD SEC Filings - Conmed Corp 10-K, 10-Q, 8-K Forms
This page provides access to CONMED Corporation's (NYSE: CNMD) U.S. Securities and Exchange Commission filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It offers AI-powered tools to interpret the information, summarizing key points, highlighting important sections, and surfacing items related to topics such as portfolio changes, capital allocation decisions, and leadership transitions. Recent filings cover a dividend declaration and an insider stock sale.
CNMD PE Ratio & Valuation, Is CNMD Overvalued
This article analyzes Conmed Corp (CNMD) valuation, concluding it is currently undervalued. Based on its forward PE ratio of 27.17, CNMD is considered undervalued compared to its five-year average, with a fair price ranging from $35.14 to $57.45. The article also compares key metrics like P/B ratio, FCF yield, and P/S ratio against historical averages and competitors.
Analysis of Key Market Segments Driving the Gastrointestinal Devices Market
The gastrointestinal devices market is projected to reach $17.46 billion by 2030, growing at an 8.3% CAGR, driven by technological advancements like AI-assisted diagnostics and expanding endoscopy solutions. Key trends include increased adoption of advanced GI endoscopic techniques, capsule endoscopy systems, and minimally invasive treatments. Major players such as Olympus Corporation and Fujifilm Holdings Corporation are focusing on innovation and strategic acquisitions to enhance their market presence and product portfolios.
Trends in Growth, Segment Analysis, and Competitive Approaches
The hand-held surgical instruments market is projected to reach $12.96 billion by 2030, growing at an 11.5% CAGR, driven by advanced surgical techniques, infection prevention, and outpatient surgeries. Key players include Johnson & Johnson, B. Braun Melsungen AG, and Zimmer Biomet Holdings Inc., with significant innovation seen in precision tools and ergonomic designs. Recent acquisitions, such as STERIS PLC's purchase of Becton, Dickinson and Company's surgical assets, are shaping the competitive landscape.
CONMED Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
CONMED Corp., a small-cap pharmaceutical company, has experienced a significant downturn in its stock performance, returning -42.22% over the past year. Technical indicators suggest a bearish sentiment, and the stock has lagged considerably behind the S&P 500 over multiple time frames, including a -65.77% return over three years. This evaluation revision highlights the ongoing challenges faced by CONMED in the current market.
